Initiating treatment with dulaglutide: Algorithms, notes and talking points

15 minutes to Delve
Contributor
Brendan Duck, Ryan Paul
25 August 2021
Dulaglutide Algorithm

From 1 September and when clinically indicated, dulaglutide can be started in adult patients with type 2 diabetes using the steps shown in this resource.

Always maintain metformin treatment if tolerated.

Talking points, relevant for all patients starting dulaglutide, are provided along with two algorithms and accompanying prescribing notes.

For a similar resource on initiating treatment with emagliflozin, click here.

References

  1. Lilly Investors. Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes [News Release]. Indianapolis: Eli Lilly and Company, 9 June 2019. https://investor.lilly.com/news-releases/news-release-details/trulicityr-dulaglutide-significantly-reduced-major
  2. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394(10193):121–30. doi: 10.1016/S0140-6736(19)31149-3
  3. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7(10):776–85. doi: 10.1016/S2213-8587(19)30249-9
  4. Edwards KL, Minze MG. Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes. Core Evid 2015;10:11–21. doi: 10.2147/CE.S55944
  5. Australian government. Therapeutic Goods Administration. Australian Product information - Trulicity (dulaglutide RCH) autoinjector. vA6.0 July 2020. https://apps.medicines.org.au/files/lyptruli.pdf
  6. Kugler AK, Thiman ML. Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data. Diabetes Metab Syndr Obes 2018;11:187–97. doi: 10.2147/DMSO.S134960
  7. Greco EV, Russo G, Giandalia A, et al. GLP-1 receptor agonists and kidney protection. Medicina (Kaunas) 2019;55(6):233. doi: 10.3390/medicina55060233
  8. Mody R, Yu M, Grabner M, et al. Dulaglutide shows sustained reduction in glycosylated hemoglobin values: 2-Year US real-world study results. Clin Ther 2020;42(11):2184–95. https://www.sciencedirect.com/science/article/pii/S0149291820304616
  9. Edwards KL, Minze MG. Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes. Core Evid 2015;10:11–21. doi: 10.2147/CE.S55944
  10. New Zealand Society for the Study of Diabetes (NZSSD), Ministry of Health. Type 2 diabetes management guidance. 2021. https://t2dm.nzssd.org.nz (Accessed July 2021).
  11. Pharmac. Decision to fund two new medicines for type 2 diabetes – Amended with Q&A. 29 January 2021. https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-fund-two-new-medicines-for-type-2-diabetes
  12. Trulicity – dulaglutide injection, solution. Instructions for use. Eli Lilly and Company, September 2020. Version 38, revised April 2021. https://uspl.lilly.com/trulicity/trulicity.html#ug (Accessed July 2021).